Momentus Inc. (MNTS): Nasdaq/NYSE listing notice — Momentus receives Nasdaq deficiency notice for bid price; Vigoride-5 maneuvering with water propulsion

Momentus Inc.

Nasdaq notified Momentus that closing bid price of Class A common stock was below $1 for 30 consecutive days; 180-day cure period ends Sept 18, 2023.
Vigoride-5 spacecraft's Attitude and Reaction Control Systems commissioned and functional using water propellant; MET thruster testing to begin.
Board amended 2022 Inducement Plan to increase shares available from 4M to 7M for new-hire awards under Nasdaq Rule 5635(c)(4).
If non-compliance persists, Momentus may be eligible for additional 180-day cure period or face delisting and potential OTC trading.

item 3.01 item 5.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Momentus Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

March 20, 2023, Momentus Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s Class A Common Stock (the “Common Stock”) for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). The Notice has no immediate impact on the listing of the Company’s common

View on SEC.gov

Browse all listing & compliance notices →

Momentus Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-013745

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.